Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion, recommending an update of the label for Tresiba® (insulin degludec) to include data from the SWITCH 1 and 2 clinical trials
Diabetes News
Tag: Novo Nordisk
Novo Nordisk receives US FDA approval for Tresiba® and Ryzodeg® 70/30
Novo Nordisk announce that the US Food and Drug Administration (FDA) has approved Tresiba® and Ryzodeg® 70/30 for the treatment of diabetes mellitus in adults after review of the class II resubmissions of the New Drug Applications (NDAs)
Novo Nordisk receives positive opinion from the European regulatory authorities for Saxenda® (liraglutide 3 mg) for the treatment of obesity
Novo Nordisk announce that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion for the use of Saxenda® (liraglutide 3 mg) for the treatment of obesity